CYB5A Induces Autophagy, and Higher Expression Improves Survival in Pancreatic Cancer

Get Permission

Loss of 18q22.3 is a prognostic marker in pancreatic ductal adenocarcinoma. In a study reported in the Journal of the National Cancer Institute, Giovannetti and colleagues assessed the role of 18q22.3-encoded CYB5A in pancreatic cancer prognosis and autophagy modulation.

In the study, both resected (n = 130) and metastatic (n = 50) patients with low CYB5A mRNA or protein expression had significantly shorter overall survival compared with patients with higher expression levels (eg, median 16.7 vs 24.8 months, P = .02, among patients with radical resection). Studies in pancreatic ductal adenocarcinoma cell lines showed that increased CYB5A expression was associated with autophagy induction and reduced proliferation and migration/invasion of cancer cells.

Network analysis of pro-autophagic signaling pathways indicated an interaction of CYB5A with TRAF6, an interaction that was confirmed by observation of downregulation of TRAF6 after CYB5A reconstitution (–69% in SU.86.86-CYB5A-positive cell lines, P = .005). CYB5A silencing restored TRAF6 expression and wound healing. Studies in CYB5A-positive orthotopic mouse models showed that CYB5A-induced autophagy, inhibited pancreatic tumor growth/metastasis, and increased survival (median, 57 vs 44 days, P = .03).

The investigators concluded, “These results define CYB5A as a novel prognostic factor for [pancreatic ductal adenocarcinoma] that exerts its tumor-suppressor function through autophagy induction and TRAF6 modulation.”

Giovannetti E, et al: J Natl Cancer Inst 106(1):djt346, 2014.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.